Searchable abstracts of presentations at key conferences in endocrinology

ea0056p1144 | Thyroid cancer | ECE2018

Changing treatment trends with radioiodine in thyroid carcinoma at the beginning of 21st century in Castilla-La Mancha (Spain)

Delgado Manuel , Sastre Julia , Quiroga Ivan , Gonzalez Javier , Torres Belvis , Aznar Silvia , Alvarez Visitacion , Herranz Sandra , Moreno Jesus , Gomez Paz

Background and objective: The incidence of differentiated thyroid carcinoma (DTC) is increasing worldwide. Radioiodine (RAI) ablation is one of the main elements in the therapy of DTC after surgical removal of the gland. This study aims to compare the use of I131 in a Spanish Cohort of DTC before and after the American Thyroid Association (ATA) 2009 guidelines.Patients and methods: The Cadit-CAM study was designed to evaluate retrospectively characterist...

ea0070aep722 | Pituitary and Neuroendocrinology | ECE2020

Doses of tolvaptan needed in chronic therapy of SIADH-induced euvolemic hyponatremia vary according to the etiology of SIADH

Pérez Candel Xavier , Lopez Nevado Celia , Cuesta Martin , Angel Rodriguez Cabezas Miguel , Puebla Virginina , de Miguel Paz , Gomez Hoyos Emilia , Ruiz Teresa , Calle Pascual Alfonso , Runkle Isabel

Introduction: Clinical trials indicate that Tolvaptan is safe and effective in the treatment of patients with sustained mild/moderate SIADH-induced euvolemic hyponatremia. Tolvaptan doses are often modified during chronic use. We present the weekly doses of a series of patients on chronic therapy, followed up in outpatient clinic.Methods: Retrospective, cross-sectional. 114 patients receiving tolvaptan for chronic SIADH were followed up in a Hyponatremia...